RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection Jan 11, 2017
DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from the Government of Canada to Support Expanded Research with Lead Product Candidate VAL-083 Jan 10, 2017
RedHill Biopharma Announces Exercise of Stock Options by Directors and Senior Management Jan 10, 2017
RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference Jan 7, 2017
Manitok Energy Inc. Announces Resignation of Chief Operating Officer and Re-Aligned Management Responsibilities Jan 6, 2017
Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA Jan 6, 2017
Resverlogix Announces Voting Results From The 2016 Annual And Special Meeting Of Shareholders Dec 17, 2016
DelMar Pharmaceuticals Receives Notice of Allowance from the US Patent and Trademark Office for Key Patent for VAL-083 Dec 15, 2016
